Eddie Hickman
Stock Analyst at Guggenheim
(3.06)
# 1,041
Out of 4,829 analysts
16
Total ratings
37.5%
Success rate
5.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $44.66 | +88.09% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.51 | +1,087.18% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $7.75 | +183.87% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $10.52 | +204.18% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $6.70 | +422.39% | 1 | Mar 13, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $12 | $1.58 | +659.49% | 3 | Jan 17, 2025 |
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $44.66
Upside: +88.09%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.51
Upside: +1,087.18%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $7.75
Upside: +183.87%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $10.52
Upside: +204.18%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $6.70
Upside: +422.39%
Outlook Therapeutics
Jan 17, 2025
Reiterates: Buy
Price Target: $12
Current: $1.58
Upside: +659.49%